Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma

Area of Science:

• Molecular Biology
• Genomics
• Cancer Research

Background:

• Current multiple myeloma (MM) risk stratification relies on clinical and genetic factors.
• These factors do not fully capture the disease's heterogeneity, necessitating novel prognostic markers.
• Understanding B cell subpopulation and MM plasma cell transcriptomics is crucial for advancing MM treatment.

Purpose of the Study:

• To identify active and alternative active promoters in B cell subpopulations and MM patient samples.
• To investigate the association between alternative promoter expression and patient survival outcomes in MM.
• To establish cancer-specific alternative active promoters as potential new prognostic tools for MM.

Main Methods:

• RNA sequencing (RNA-seq) was employed to analyze gene expression in B cell subpopulations and MM patient samples.
• Chromatin-based promoter definitions were used to validate RNA-seq findings.
• The CoMMpass dataset, comprising 595 MM patient samples, was utilized to correlate alternative promoter expression with survival data.

Main Results:

• Active and alternative promoter expression was found to be specific to B cell subpopulations and MM plasma cells.
• Expression patterns showed high consistency with chromatin-based promoter definitions.
• Alternative promoter expression was significantly associated with reduced progression-free and overall survival in MM patients, independent of genetic alterations.

Conclusions:

• Cancer-specific alternative active promoters represent novel transcriptomic features in multiple myeloma.
• These promoters offer a new avenue for improving prognostic stratification in MM patients.
• The findings highlight the potential of alternative promoter analysis for personalized MM therapy.